CAMBRIDGE, MA--(Marketwire -05/22/12)- Relay Technology Management (Relay TM) today announced the official launch of Business Development Live (BD Live!) -- a new unified, real-time data visualization, comparative asset analysis and tracking platform for the life sciences industry. Relay TM supports life science business development and licensing professionals validate opportunities and discover new assets.
"BD Live! provides access to a comprehensive information repository on biopharma assets and other relevant entities and utilizes cutting-edge data visualization technologies to create interactive dashboards that dramatically improve the user experience," says David Greenwald, Ph.D., Relay TM's co-founder and managing director. "We are excited to open the platform more broadly after having successfully tested our innovative approach with a number of leading pharmaceutical and biotech companies. We look forward to working with customers to fulfill their business intelligence needs."
"Identifying and evaluating assets, and finding the most appropriate partners for pharmaceutical companies is time-consuming, resource-intensive and often based on partial information," shares Peter Collins, business intelligence director at Nature Publishing Group, which created a collaborative partnership with Relay and made a strategic investment in the company in 2011. "Relay is uniquely positioned to bring much needed objective data aggregation and analysis to speed up the drug development process."
Relay TM complements competitive intelligence by assessing the relative attractiveness of life science assets -- drugs, targets, researchers, and institutions, historically and in real time, from one screen. BD Live! is offered as a Software-as-a-Service subscription service with the following components:
- Comprehensive, real-time life sciences industry business intelligence: BD Live! aggregates and visualizes data from a comprehensive list of life science sources, including 27 million data points and growing -- representing a combination of scientific and business literature, technology transfer data, and clinical trial data. The platform harvests these data sources for daily updates and latest industry developments.
- Unified life sciences trend monitoring and comparative asset analysis: BD Live! offers real-time, analytical and customizable dashboards on drug profiles and targets, researchers and institutions based on their relative attractiveness within specific therapeutic areas. This enables life sciences professionals to rapidly compare related categories, such as emerging drug targets and approaches in a particular therapeutic area.
BD Live! enables comparative asset analysis via an industry-first Relative Valuation Index (RVI). The Relay RVI accounts for the stage of asset development and factors in competitive environment, scientific evidence, investments, proof of mechanism, research momentum, FDA and transactional trends, among other variables. The Relay RVI is insulated from popular opinion to ensure robust and objective assessment of assets.
"We are building Relay with the vision for it to become the Bloomberg of the life sciences industry," adds Brigham Hyde, Ph.D., co-founder and managing director of Relay TM. "Much like Bloomberg helped to streamline the bond market and bring an objective standard to bond valuations, Relay aims to bring data-driven decision making to the life sciences industry."
About Relay Technology Management
Relay Technology Management (http://www.relaytm.com) is a life sciences trend analytics and asset valuation software provider. The company's Relay Innovation Engine software platform powers BD Live! to support business development and corporate strategy professionals in the life science industry confirm the attractiveness of assets under consideration and unearth new technologies. Relay aims to increase the efficiency of drug development by offering a transparent, objective and scalable approach to rapid asset analysis.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1989964